FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1920447776> ?p ?o ?g. }

• W1920447776 endingPage "4070" @default.
• W1920447776 startingPage "4061" @default.
• W1920447776 abstract "Article10 November 2005free access SOD2 overexpression: enhanced mitochondrial tolerance but absence of effect on UCP activity José P Silva José P Silva Department of Laboratory Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden Search for more papers by this author Irina G Shabalina Irina G Shabalina The Wenner-Gren Institute, The Arrhenius Laboratories F3, Stockholm University, Stockholm, Sweden Search for more papers by this author Eric Dufour Eric Dufour Department of Laboratory Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden Search for more papers by this author Natasa Petrovic Natasa Petrovic The Wenner-Gren Institute, The Arrhenius Laboratories F3, Stockholm University, Stockholm, Sweden Search for more papers by this author Emma C Backlund Emma C Backlund The Wenner-Gren Institute, The Arrhenius Laboratories F3, Stockholm University, Stockholm, Sweden Search for more papers by this author Kjell Hultenby Kjell Hultenby Clinical Research Center, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden Search for more papers by this author Rolf Wibom Rolf Wibom Department of Laboratory Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden Search for more papers by this author Jan Nedergaard Jan Nedergaard The Wenner-Gren Institute, The Arrhenius Laboratories F3, Stockholm University, Stockholm, Sweden Search for more papers by this author Barbara Cannon Barbara Cannon The Wenner-Gren Institute, The Arrhenius Laboratories F3, Stockholm University, Stockholm, Sweden Search for more papers by this author Nils-Göran Larsson Corresponding Author Nils-Göran Larsson Department of Laboratory Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden Search for more papers by this author José P Silva José P Silva Department of Laboratory Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden Search for more papers by this author Irina G Shabalina Irina G Shabalina The Wenner-Gren Institute, The Arrhenius Laboratories F3, Stockholm University, Stockholm, Sweden Search for more papers by this author Eric Dufour Eric Dufour Department of Laboratory Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden Search for more papers by this author Natasa Petrovic Natasa Petrovic The Wenner-Gren Institute, The Arrhenius Laboratories F3, Stockholm University, Stockholm, Sweden Search for more papers by this author Emma C Backlund Emma C Backlund The Wenner-Gren Institute, The Arrhenius Laboratories F3, Stockholm University, Stockholm, Sweden Search for more papers by this author Kjell Hultenby Kjell Hultenby Clinical Research Center, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden Search for more papers by this author Rolf Wibom Rolf Wibom Department of Laboratory Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden Search for more papers by this author Jan Nedergaard Jan Nedergaard The Wenner-Gren Institute, The Arrhenius Laboratories F3, Stockholm University, Stockholm, Sweden Search for more papers by this author Barbara Cannon Barbara Cannon The Wenner-Gren Institute, The Arrhenius Laboratories F3, Stockholm University, Stockholm, Sweden Search for more papers by this author Nils-Göran Larsson Corresponding Author Nils-Göran Larsson Department of Laboratory Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden Search for more papers by this author Author Information José P Silva1, Irina G Shabalina2, Eric Dufour1, Natasa Petrovic2, Emma C Backlund2, Kjell Hultenby3, Rolf Wibom1, Jan Nedergaard2, Barbara Cannon2 and Nils-Göran Larsson 1 1Department of Laboratory Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden 2The Wenner-Gren Institute, The Arrhenius Laboratories F3, Stockholm University, Stockholm, Sweden 3Clinical Research Center, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden *Corresponding author. Division of Metabolic Diseases, Department of Laboratory Medicine, Karolinska Institutet, Karolinska University Hospital, Novum, 141 86 Huddinge, Stockholm, Sweden. Tel.: +46 8 5858 3724; Fax: +46 8 779 5383; E-mail: [email protected] The EMBO Journal (2005)24:4061-4070https://doi.org/10.1038/sj.emboj.7600866 PDFDownload PDF of article text and main figures. ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinked InMendeleyWechatReddit Figures & Info We have created P1 artificial chromosome transgenic mice expressing the human mitochondrial superoxide dismutase 2 (SOD2) and thus generated mice with a physiologically controlled augmentation of SOD2 expression leading to increased SOD2 enzyme activities and lowered superoxide levels. In the transgenic mice, effects on mitochondrial function such as enhanced oxidative capacity and greater resistance against inducers of mitochondrial permeability were observed. Superoxide in the mitochondrial matrix has been proposed to activate uncoupling proteins (UCPs), thus providing a feedback mechanism that will lower respiratory chain superoxide production by increasing a proton leak across the inner mitochondrial membrane. However, UCP1 and UCP3 activities and mitochondrial ATP production rates were not altered in isolated mitochondria from SOD2 transgenic mice, despite lowered superoxide levels. Globally, the transgenic mice displayed normal resting metabolic rates, indicating an absence of effect on any UCP activities, and normal oxygen consumption responses after norepinephrine injection. These results strongly suggest that endogenously generated matrix superoxide does not regulate UCP activity and in vivo energy expenditure. Introduction Manganese superoxide dismutase 2 (SOD2) is a critical mitochondrial antioxidant defense against superoxide produced by respiration. Homozygous SOD2 knockout mice develop severe symptoms in heart (Li et al, 1995) and brain (Lebovitz et al, 1996; Melov et al, 1998) leading to early postnatal death. Heterozygous SOD2 knockout mice exhibit numerous alterations in mitochondrial function such as a reduction in complex I and II activities, lowered aconitase activity (Melov et al, 1999), increased susceptibility for induction of permeability transition (Kokoszka et al, 2001), ultrastructural abnormalities (mitochondrial swelling) and enhanced lipid peroxidation (Strassburger et al, 2005). Correspondingly, SOD2 overexpression protects mitochondrial respiratory function and blocks apoptosis induction during heart ischemia–reperfusion injury (Suzuki et al, 2002), and attenuates mitochondrial reactive oxygen species (ROS) generation, intracellular lipid peroxidation and cell death (Motoori et al, 2001). However, the antioxidative effect of SOD is strongly dependent on its expression level. Excessive SOD overexpression may significantly alter the levels of related ROS and cause enhanced lipid peroxidation and hypersensitivity to ROS (Kowald and Klipp, 2004). Careful regulation of SOD expression is thus critical in order for cells and tissues to benefit from its antioxidative effect. Introduction of large genomic sequences into the mouse genome by P1 artificial chromosomes (PAC) confers physiological control of gene expression due to the presence of both positive and negative regulatory sequence elements. Here, we used this transgenic approach to overexpress SOD2, particularly to study the regulation of uncoupling protein (UCP) activities by superoxide. The UCPs belong to the large family of mitochondrial inner membrane carriers. The first identified UCP isoform, UCP1, is specifically expressed in brown adipose tissue (BAT) and confers a regulated proton leak across the inner mitochondrial membrane (Cannon and Nedergaard, 2004). Two other UCP isoforms, UCP2 and UCP3, were identified based on sequence homology to UCP1 (Ricquier and Bouillaud, 2000), but their physiological functions remain elusive (Nedergaard and Cannon, 2003; Brand and Esteves, 2005). UCP function has been implicated in the control of ROS homeostasis. Macrophages from UCP2 knockout mice have increased ROS levels (Arsenijevic et al, 2000). UCP3 knockout mice display signs of increased oxidative damage in muscle mitochondria, indicative of increased ROS production (Brand et al, 2002). In both mice and rats, generation of superoxide by xanthine plus xanthine oxidase increases the proton conductance in mitochondria expressing UCP3 (skeletal muscle), as well as in mitochondria expressing UCP1 (BAT) and UCP2 (kidney, pancreatic β-cells, spleen) (Echtay et al, 2002b), suggesting that superoxide activates all UCP isoforms in vitro. This effect is inhibited by addition of SOD, by GDP or by molecules that bind fatty acids. Activation of the UCPs by superoxide has been indicated to occur from the matrix side (Echtay et al, 2002a; Talbot et al, 2004). Mitochondrial uncoupling is expected to result in a more oxidized state of the electron transport chain, thereby preventing superoxide generation (Korshunov et al, 1997). Superoxide-mediated activation of UCPs has therefore been proposed to serve as a negative feedback mechanism to limit further superoxide production (Echtay et al, 2002b). Superoxide-mediated activation of UCPs may also be expected to have a significant regulatory effect on energy metabolism, due to the widespread expression of UCP2 and UCP3. However, the hypothesis that superoxide activates UCPs is not universally accepted (Couplan et al, 2002). Many of the studies described above were performed in isolated mitochondria exposed to exogenous superoxide, and only one study has indicated that superoxide-stimulated UCP-mediated uncoupling might also occur in vivo (Krauss et al, 2003). In the genetically modified mouse strain used here having a regulated increase of SOD2 enzyme activity, superoxide levels were reduced and effects on mitochondrial function were observed. However, UCP1 and UCP3 activities were not altered in isolated mitochondria in SOD2-overexpressing mice, which also showed normal resting metabolic rates (indicating no global effects on any UCP activities). The results strongly suggest that endogenously generated superoxide does not regulate UCP activity and energy expenditure in vivo. Results and discussion Creation and characterization of mice with increased SOD2 enzyme activity We created transgenic mice with an increased SOD2 enzyme activity by introducing PAC clones with the human SOD2 gene into the mouse. The chosen transgenic strategy has several advantages. The large size of the PAC clones will make it likely that all sequence elements needed for physiological regulation of gene expression are present and will minimize positional effects caused by random integration of the transgene (Heintz, 2000). The use of specific probes for human SOD2 makes it easy to establish that the transgene is present and expressed in the transgenic mice (Ekstrand et al, 2004) and the overexpression will be within a physiologically relevant interval (Ekstrand et al, 2004). We screened a human genomic PAC library for the presence of the SOD2 gene and identified 16 positive clones. The clones were ordered in a contig by using Southern blotting with end probes (generated by vectorette PCR) and by size determination with pulsed-field gel electrophoresis as described previously (Ekstrand et al, 2004). Three PAC clones with overlapping 5′ and 3′ sequences (Figure 1A) named PAC662, PAC817 and PAC737 were chosen for pronuclear injections of embryos of the inbred FVB/N mouse strain. We performed Southern blots with a human SOD2 cDNA probe and found integration of the human SOD2 gene into the mouse genome without signs of any rearrangements (Figure 1B). We obtained germline transmission from nine of 12 founder animals (Figure 1B). Two independent lines, PAC662D1 (from the founder D1 of clone PAC662) and PAC737D2 (from the founder D2 of clone PAC737), were characterized further (Figure 1B). The transgenes of these two lines were constantly transmitted at less than the expected Mendelian ratio of 50% (PAC662D1 34% and PAC737D2 38%; P<0.001, χ2 test for uneven genotype distribution). Increased expression of SOD2 thus had some effects on fertility, consistent with a previous report (Raineri et al, 2001). Western blot analyses with a polyclonal antibody against human SOD2 demonstrated expression of the human SOD2 protein mainly in kidney and muscle in the PAC737D2 line (Figure 1C) and a widespread tissue distribution in the PAC662D1 line (Figure 1C and D). In the PAC737D2 line, SOD enzyme activity was increased in isolated mitochondria from skeletal muscle only (Figure 1E), but in the PAC662D1 line, increased activities were found in all tissues examined (Figure 1E). The observed SOD enzyme activity pattern (Figure 1E) was thus consistent with the observed human SOD2 protein expression pattern (Figure 1C). Further studies were focused on the PAC662D1 line. Figure 1.Creation of SOD2-overexpressing mice. (A) Contig of the PAC clones used to generate transgenic mice. (B) Southern blot analysis of tail DNA from transgenic founder animals probed with human SOD2 cDNA. The blot was rehybridized with an 18S rDNA probe to assess loading. Human DNA and FVB/N mouse DNA were used as controls. Symbols are used to indicate the founders with germline transmission of the SOD2 transgene (+) and the lines studied further (*). (C) Western blot analysis of levels of human SOD2 protein in different tissues. β-Actin was used for information on loading. β-Actin is not present in heart and muscle. (D) Western blot analysis of levels of human SOD2 protein (hSOD2) in BAT of wild-type or SOD2-overexpressing mice of the PAC662D1 line acclimated to 25 and 4°C. β-Actin was used as a loading control. (E) SOD enzyme activity in mitochondria from different tissues of wild-type (gray bars) and SOD2-overexpressing mice (black bars) (n=3–5). Download figure Download PowerPoint As seen in Supplementary Figure 1, no evidence was found that indicated any influence of SOD overexpression on mitochondrial biogenesis or gene expression. SOD2 overexpression lowers superoxide release rates Net superoxide release rates were assessed directly in isolated skeletal muscle and brown fat mitochondria and in mouse embryonic fibroblasts (MEF) by fluorescence with the dye dihydroethidium (DHE) (Benov et al, 1998). The conversion of DHE to ethidium is superoxide-induced, and the fluorescence emitted by the ethidium formed was followed. A chemical validation of this method was first performed. Generation of superoxide by the xanthine plus xanthine oxidase system in the presence of DHE resulted in a significant increase in ethidium-emitted fluorescence (Figure 2A, upper panel). This was blocked by further addition of recombinant SOD (Figure 2A, upper panel). The method was then biologically validated. Wild-type mitochondria incubated with succinate and rotenone showed a linear increase in fluorescence (Figure 2A, lower panel). Antimycin A was added as a positive control to enhance mitochondrial superoxide generation. This resulted in a much more pronounced increase in fluorescence that was inhibited by further addition of recombinant SOD (Figure 2A, lower panel). This assay thus detected mitochondrial superoxide release. Skeletal muscle mitochondria were therefore incubated under conditions of reverse electron flow, that is, in the presence of succinate without rotenone, to promote superoxide generation (Figure 2B). The resulting endogenous superoxide release rate was of the same order of magnitude as that generated exogenously (Figure 2A, upper panel). PAC662D1 mitochondria displayed a lower increase in ethidium-emitted fluorescence compared with wild-type mitochondria (Figure 2B and C), thus demonstrating reduced superoxide release rates under reverse electron flow conditions compared with wild-type mitochondria. A similar reduction in superoxide release rate was observed in brown fat mitochondria under all conditions tested (Figure 2D). Figure 2.Superoxide measurements. (A) Validation. Upper panel: Chemical validation. Sequential addition of 63.5 μM DHE, 375 μM xanthine (X), 5 μg/ml xanthine oxidase (XO) and 68 U/ml recombinant SOD was performed and fluorescence emission was followed. Lower panel: Biological validation. Mitochondria, 0.5 mg, from skeletal muscle were incubated with 5 mM succinate, 2 μg/ml oligomycin and 3.3 μg/ml rotenone followed by addition of 63.5 μM DHE. Further additions of 0.8 μg/ml antimycin A and of 24 U/ml recombinant SOD were made. (B) Mitochondria, 0.5 mg, from skeletal muscle (as in B) were incubated under conditions of reverse electron flow using 5 mM succinate and 2 μg/ml oligomycin followed by addition of 63.5 μM DHE. (C) Quantification of the change in fluorescence signal intensity over time under conditions of reverse electron flow as exemplified in (B). The rate of superoxide release was calculated as the change in fluorescence intensity during the linear response after addition of DHE. The y-axis denotes the rate of superoxide release in PAC662D1 mitochondria (black bar) relative to wild-type mitochondria (gray bar) and is given in percentage. The values represent the means±s.e.m. (n=3 independent mitochondrial preparations, each analyzed in triplicate). (D) The rate of superoxide release from brown fat mitochondria under conditions similar to those in (B) but with 5 mM glycerol-3-phosphate as substrate and 3.3 μg/ml rotenone. Other conditions (e.g. presence/absence of GDP or rotenone) yielded similarly decreased superoxide release rates in the SOD2-overexpressing mitochondria (not shown) (n=3 independent mitochondrial preparations, each analyzed in triplicate). (E) Superoxide measurements of PAC662D1 (black bar) and wild-type (gray bar) MEF. MEF were incubated in Dulbecco's modified Eagle's medium (DMEM) containing 10 μM DHE. The change in fluorescence signal intensity of each cell was monitored online by confocal microscopy. For statistical analyses, data from six separate experiments were pooled. The values represent the means±s.e.m. (hSOD2, n=198; wild type, n=201). (F) Aconitase enzyme activity measurements in PAC662D1 (black bar) and wild-type skeletal muscle mitochondria (gray bar). The values represent the means±s.e.m. (n=5). Download figure Download PowerPoint We then investigated whether SOD2 overexpression altered superoxide levels in vivo. Superoxide levels were determined in MEF isolated from PAC662D1 mice and from wild-type littermate controls. MEF were incubated in the presence of DHE and monitored online by confocal microscopy (Krauss et al, 2003). MEF of PAC662D1 mice showed a reduced increase in fluorescence signal intensity over time compared with wild-type MEF (Figure 2E). As a positive control, MEF were incubated with 10 μM antimycin A, which led to a 150% increase in ethidium-emitted fluorescence (not shown). These results thus demonstrate lowered endogenous superoxide release rates in SOD2-overexpressing MEF. Aconitase enzyme activities are readily and specifically impaired by superoxide (Gardner et al, 1995). Higher aconitase enzyme activities were found in PAC662D1 mitochondria compared with wild-type mitochondria (Figure 2F). We conclude that SOD2 overexpression reduced net superoxide release rates in isolated mitochondria and in MEF. SOD2 overexpression increases resistance to inducers of mitochondrial permeability Oxidative stress results in damage of cellular membranes (Davies, 1995). Mitochondria isolated from heterozygous SOD2 knockout mice are more prone to undergo permeability transition (Kokoszka et al, 2001). In order to investigate the functional significance of the SOD2 overexpression, liver and muscle mitochondria were isolated from wild-type and PAC662D1 mice. They showed no spontaneous swelling when incubated for 30 min at 37°C (Figure 3A and B). High-amplitude swelling was induced by addition of Ca2+ (Figure 3A) or oleate (Figure 3B), and somewhat less swelling was observed in PAC662D1 mitochondria in comparison with wild-type mitochondria. The response to alamethicin, which induces maximal mitochondrial swelling, was greater in PAC662D1 mitochondria, showing that prior to the addition of alamethicin, these mitochondria were significantly less swollen than wild-type mitochondria (Figure 3C). We thus conclude that SOD2 overexpression confers enhanced resistance to induction of mitochondrial permeability. These data are in line with reports of enhanced ROS production and cardiolipin peroxidation in liver mitochondria undergoing Ca2+- or fatty acid-induced permeability transition (Catisti and Vercesi, 1999; Petrosillo et al, 2004). The increased resistance to induction of mitochondrial permeability conferred by SOD2 overexpression probably results from lowered generation of hydroxyl (OH•) radicals by the Fenton reaction leading to lowered lipid peroxidation of the inner mitochondrial membrane (Brand et al, 2004). Figure 3.Induction of mitochondrial high-amplitude swelling. (A) Ca2+-induced swelling of liver mitochondria isolated from wild-type (Wt, thin lines) or SOD2-overexpressing (hSOD2, thick lines) mice. The substrate used was 5 mM each of glutamate and malate. Arrows indicate the time points for addition of 30 μM Ca2+ and 10 μg/ml alamethicin. (B) Oleate-induced swelling of skeletal muscle mitochondria from wild-type (Wt, thin lines) or SOD2-overexpressing mice (hSOD2, thick lines). The substrate used was 5 mM each of pyruvate and malate. Arrows indicate the time points for addition of 180 μM oleate and 10 μg/ml alamethicin. (C) Quantification of the amplitude of swelling 20 min after the addition of Ca2+ or oleate. Values are indicated in percent of the maximum response (defined as the absorbance difference between the starting value and the value after alamethicin addition) in mitochondria from wild-type (gray bars) or SOD2-overexpressing (black bars) mice (n=3 independent mitochondrial preparations, each analyzed in duplicate). Download figure Download PowerPoint SOD2 overexpression does not diminish basal proton leak but enhances mitochondrial oxidative capacity If matrix superoxide is a significant activator of UCPs, mitochondria overexpressing SOD2 would be expected to show a markedly lower basal respiration because of reduced proton leak. To examine this, mitochondria were isolated from tissues with different expression of UCPs, that is, liver, brain, skeletal muscle and BAT, and respiratory chain function was measured (Figure 4 and Tables I and and II). In liver mitochondria, which lack all three UCPs, no difference in basal (i.e. state 4, after oligomycin addition) respiration was observed (Table I). Also in brain mitochondria (that have been reported to express UCP2) and in skeletal muscle mitochondria (that express UCP3), SOD2 overexpression failed to influence state 4 respiration (Table I). In brown fat mitochondria, which express UCP1, the equivalent respiration (after GDP addition) was also unchanged (Table II). As an alternative indicator for the basal proton leak, the mitochondrial membrane potential (MMP) was also measured but was found to be unaltered (Table I). Thus, these data indicate that, in the basal state, mitochondrial superoxide does not have an observable activating effect on proton conductance mediated by UCPs (or by any other mitochondrial proteins). Figure 4.Mitochondrial respiratory measurements. (A) Measurement of oxygen consumption in skeletal muscle mitochondria (SM). FCCP was added successively to reach a final concentration of 1.4 μM. (B) Measurement of oxygen consumption in brown fat mitochondria (BM). Palmitoyl-L-carnitine (PLC), GDP and FCCP (to a final concentration of 2.8 μM) were added as indicated. (C) Correlation between mitochondrial oxidative capacity and mitochondrial SOD enzyme activity. The respiratory measurements were performed as described in (A, B) and the SOD enzyme activities as in Figure 1E. The relative increase in mitochondrial oxidative capacity after FCCP addition (mutant/wild type, %, calculated from the parallel preparations each day) was plotted against the relative increase in mitochondrial SOD enzyme activity (mutant/wild type, %). The results are from 2–5 independent experiments. Download figure Download PowerPoint Table 1. Parameters of oxidative phosphorylation and MMP in different tissues State 3 State 4 State 3/state 4 Unc. (FCCP) Unc./state 4 MMP Liver Wild type (n=3) 118±5 21.8±0.7 5.5±0.4 173±2 7.9±0.1 hSOD2/+ (n=3) 119±3 21.1±0.4 5.7±0.1 182±2* 8.6±0.2 Brain Wild type (n=3) 87±9 10.6±0.9 8.9±0.9 170±10 18.6±1.6 hSOD2/+ (n=2) 99±10 9.8±1.6 10.9±1.4 189±4* 19.1±1.9 Skeletal muscle Wild type (n=5) 249±8 15.0±1.4 16.0±1.2 505±10 33.6±2.9 179±6 hSOD2/+ (n=4) 252±7 14.5±1.2 17.6±1.3 577±4* 39.5±3.1 180±10 Values are from experiments as illustrated in Figure 4A and are expressed as nmol O2/min mg protein. Substrates for brain and muscle are 5 mM pyruvate and for liver 5 mM glutamate, all with 3 mM malate. State 3 respiration is after 450 μM ADP and state 4 after oligomycin (2 μg/ml). Uncoupled state is that after FCCP (1.4 μM) and is denoted by Unc. MMP refers to the mitochondrial membrane potential in state 4 and is expressed in mV. Table 2. Respiration measurements in brown fat mitochondria Substrate GDP UCP1 dependent (substrate−GDP) Uncoupled state (FCCP) PLC+malate Wild type (n=4) 209±8 45.0±1.4 164±9 260±3 hSOD2/+ (n=4) 211±7 40.5±2.2 170±8 277±4* Pyruvate+malate Wild type (n=4) 160±15 42.2±2.9 118±5 231±8 hSOD2/+ (n=5) 168±11 40.3±2.6 128±9 251±10* Values are from experiments as illustrated in Figure 4B and are expressed as nmol O2/min 1 mg protein. PLC (palmitoyl carnitine) 50 μM, pyruvate 5 mM, malate 3 mM. ADP-stimulated state 3 respiration in liver, brain and muscle was unaffected by the SOD2 overexpression (Table I). However, in all tissues, effects of SOD2 overexpression were observed on maximal respiratory chain capacity (after FCCP addition; Tables I and II). We plotted the relative increase in mitochondrial oxidative capacity caused by SOD2 overexpression against the relative increase in SOD enzyme activity and obtained a linear correlation (Figure 4C). This increase in mitochondrial oxidative capacity of SOD2-overexpressing mitochondria is probably explained by the protection of superoxide-sensitive iron–sulfur clusters in enzymes of the Krebs cycle such as aconitase (Gardner et al, 1995) and subunits of the electron transport chain (Zhang et al, 1990). The higher aconitase activity of PAC662D1 skeletal muscle mitochondria (Figure 2F) supports this view. Unchanged UCP1 activity in SOD2-overexpressing BAT mitochondria The basal proton leak in BAT mitochondria was not affected by SOD2 overexpression. It is well accepted that respiration inhibitable by GDP in BAT mitochondria is mediated by UCP1 (see Figure 4B). The UCP1-mediated respiration was identical in wild-type and PAC662D1 BAT mitochondria (Table II). This result indicates that maximal UCP1 activity is independent of SOD2 activity and hence of matrix superoxide levels. It has been suggested that the superoxide activation of UCPs is fatty acid dependent (Echtay et al, 2002b). UCP1 was therefore activated by fatty acids as described previously (Shabalina et al, 2004) and it was examined whether the sensitivity to fatty acids was influenced by SOD2 overexpression (Figure 5A). SOD2 overexpression did not influence sensitivity to fatty acids (Km of wild type=24±5 nM, n=5 and of PAC662D1=26±8 nM, n=5), indicating that the fatty acid effect is not influenced by superoxide (Figure 5B). We also investigated whether SOD2 overexpression affected the GDP-mediated inhibition of UCP1 (Figure 5C and D). Also here, no influence of SOD2 overexpression could be observed (Km of wild type=162±25 μM, n=3 and of PAC662D1=168±28 μM, n=3). Figure 5.Regulation of UCP1 activity in brown fat mitochondria. (A) Oleate and (C) GDP titration of oxygen consumption in wild-type brown fat mitochondria (BM) using pyruvate (Pyr) as a substrate. Different amounts of oleate (20–120 μM) and GDP (100–2300 μM) were added at time points indicated by arrows. In (A), GDP was used at a final concentration of 1 mM. (B) oleate- and (D) GDP–response curves of oxygen consumption in BM of wild-type and SOD2-overexpressing mice, compiled from five independent experiments (means±s.e.m.) as shown in (A) and (C), respectively. The x-axis in (B) refers to the free oleate concentration. (E) GDP–response curve of oxygen consumption compiled from five independent experiments (means±s.e.m.) as shown in (C) but using glycerol-3-phosphate instead of pyruvate as substrate. Download figure Download PowerPoint These measurements were then repeated with glycerol 3-phosphate, which gives rise to superoxide (hydrogen peroxide) in these mitochondria (Drahota et al, 2002), as in other mitochondria (Miwa and Brand, 2005). Similar oxygen consumption rates were found in SOD2-overexpressing and control mitochondria (Figure 5E), and GDP titration experiments showed no significant difference between wild-type (Km=169±30 μM, n=5) and PAC662D1 (Km=146±28 μM, n=5) BAT mitochondria (Figure 5E). Thus, even when superoxide generation was augmented, no effects of SOD2 overexpression on UCP1 activity or on GDP sensitivity were observed. (The levels of UCP1 protein were similar in BAT from wild-type and PAC662D1 mice (Supplementary Figure 1D).) Unchanged UCP3 act" @default.
• W1920447776 created "2016-06-24" @default.
• W1920447776 creator A5007422379 @default.
• W1920447776 creator A5019030826 @default.
• W1920447776 creator A5019374149 @default.
• W1920447776 creator A5040041293 @default.
• W1920447776 creator A5068452147 @default.
• W1920447776 creator A5073116330 @default.
• W1920447776 creator A5077428949 @default.
• W1920447776 creator A5080492699 @default.
• W1920447776 creator A5082217331 @default.
• W1920447776 creator A5089321330 @default.
• W1920447776 date "2005-11-10" @default.
• W1920447776 modified "2023-10-18" @default.
• W1920447776 title "SOD2 overexpression: enhanced mitochondrial tolerance but absence of effect on UCP activity" @default.
• W1920447776 cites W1533321987 @default.
• W1920447776 cites W1594539479 @default.
• W1920447776 cites W1614231230 @default.
• W1920447776 cites W1750690213 @default.
• W1920447776 cites W1970881583 @default.
• W1920447776 cites W1975734027 @default.
• W1920447776 cites W1983729336 @default.
• W1920447776 cites W1983732035 @default.
• W1920447776 cites W1984156802 @default.
• W1920447776 cites W1985977889 @default.
• W1920447776 cites W1992678387 @default.
• W1920447776 cites W2009785737 @default.
• W1920447776 cites W2016655414 @default.
• W1920447776 cites W2024007747 @default.
• W1920447776 cites W2024253991 @default.
• W1920447776 cites W2025664849 @default.
• W1920447776 cites W2026399274 @default.
• W1920447776 cites W2032301380 @default.
• W1920447776 cites W2032814494 @default.
• W1920447776 cites W2036351079 @default.
• W1920447776 cites W2036573181 @default.
• W1920447776 cites W2041738481 @default.
• W1920447776 cites W2042138106 @default.
• W1920447776 cites W2043085507 @default.
• W1920447776 cites W2052622056 @default.
• W1920447776 cites W2058821788 @default.
• W1920447776 cites W2069747130 @default.
• W1920447776 cites W2069818810 @default.
• W1920447776 cites W2072593346 @default.
• W1920447776 cites W2083714336 @default.
• W1920447776 cites W2084255431 @default.
• W1920447776 cites W2094655287 @default.
• W1920447776 cites W2104606170 @default.
• W1920447776 cites W2106090797 @default.
• W1920447776 cites W2118397007 @default.
• W1920447776 cites W2121338998 @default.
• W1920447776 cites W2124055916 @default.
• W1920447776 cites W2127265700 @default.
• W1920447776 cites W2128569391 @default.
• W1920447776 cites W2132358997 @default.
• W1920447776 cites W2135805245 @default.
• W1920447776 cites W2146651397 @default.
• W1920447776 cites W2336445431 @default.
• W1920447776 cites W2336962972 @default.
• W1920447776 cites W2403757206 @default.
• W1920447776 cites W4236728311 @default.
• W1920447776 cites W4251437941 @default.
• W1920447776 doi "https://doi.org/10.1038/sj.emboj.7600866" @default.
• W1920447776 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1356306" @default.
• W1920447776 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16281056" @default.
• W1920447776 hasPublicationYear "2005" @default.
• W1920447776 type Work @default.
• W1920447776 sameAs 1920447776 @default.
• W1920447776 citedByCount "107" @default.
• W1920447776 countsByYear W19204477762012 @default.
• W1920447776 countsByYear W19204477762013 @default.
• W1920447776 countsByYear W19204477762014 @default.
• W1920447776 countsByYear W19204477762015 @default.
• W1920447776 countsByYear W19204477762016 @default.
• W1920447776 countsByYear W19204477762017 @default.
• W1920447776 countsByYear W19204477762018 @default.
• W1920447776 countsByYear W19204477762019 @default.
• W1920447776 countsByYear W19204477762020 @default.
• W1920447776 countsByYear W19204477762021 @default.
• W1920447776 countsByYear W19204477762022 @default.
• W1920447776 countsByYear W19204477762023 @default.
• W1920447776 crossrefType "journal-article" @default.
• W1920447776 hasAuthorship W1920447776A5007422379 @default.
• W1920447776 hasAuthorship W1920447776A5019030826 @default.
• W1920447776 hasAuthorship W1920447776A5019374149 @default.
• W1920447776 hasAuthorship W1920447776A5040041293 @default.
• W1920447776 hasAuthorship W1920447776A5068452147 @default.
• W1920447776 hasAuthorship W1920447776A5073116330 @default.
• W1920447776 hasAuthorship W1920447776A5077428949 @default.
• W1920447776 hasAuthorship W1920447776A5080492699 @default.
• W1920447776 hasAuthorship W1920447776A5082217331 @default.
• W1920447776 hasAuthorship W1920447776A5089321330 @default.
• W1920447776 hasBestOaLocation W19204477761 @default.
• W1920447776 hasConcept C153911025 @default.
• W1920447776 hasConcept C2775838275 @default.
• W1920447776 hasConcept C2776108821 @default.
• W1920447776 hasConcept C2776151105 @default.
• W1920447776 hasConcept C28859421 @default.

• next